AstraZeneca Acquires Drugs From Almirall | Chemical & Engineering News
Volume 92 Issue 31 | p. 19 | Concentrates
Issue Date: August 4, 2014

AstraZeneca Acquires Drugs From Almirall

Department: Business
Keywords: pharmaceuticals, acquisitions, drug delivery, respiratory drugs

AstraZeneca will pay up to $2.1 billion for the respiratory drug business of Spain’s Almirall. The deal includes both marketed products and development-stage candidates. AstraZeneca is paying $875 million up front and the rest as products hit development and sales milestones. It also will get a subsidiary focused on devices for delivering respiratory drugs. In 2013, Almirall had sales of $1.1 billion. It will now focus on dermatology drugs and other specialty pharmaceuticals.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment